Lara Meisner - 20 Dec 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
General Counsel and Secretary
Signature
/s/ Kristian Humer, Attorney-in-Fact for Lara Meisner
Issuer symbol
VRDN
Transactions as of
20 Dec 2022
Net transactions value
-$103,592
Form type
4
Filing time
22 Dec 2022, 15:42:42 UTC
Previous filing
19 Dec 2022
Next filing
25 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $13,818 +600 $23.03 600 20 Dec 2022 Direct
transaction VRDN Common Stock Sale $16,842 -600 -100% $28.07 0 20 Dec 2022 Direct F1
transaction VRDN Common Stock Options Exercise $375,988 +16,326 $23.03 16,326 21 Dec 2022 Direct
transaction VRDN Common Stock Sale $476,556 -16,326 -100% $29.19 0 21 Dec 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -600 -0.97% $0.000000 61,047 20 Dec 2022 Common Stock 600 $23.03 Direct F3
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -16,326 -27% $0.000000 44,721 21 Dec 2022 Common Stock 16,326 $23.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.03 to $28.09. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.01 to $29.5665. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.